Business Context and Reporting Period
Company: CVS Corporation (CVS)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended January 3, 2004 (53 weeks)
Industry: Retail Drugstore and Pharmacy Benefit Management (PBM)
CVS is the second-largest retail drugstore chain in the United States by sales. As of January 3, 2004, the company operated 4,179 retail and specialty pharmacy stores across 32 states and the District of Columbia. Operations are divided into two primary businesses: Retail Pharmacy (95% of consolidated net sales) and Pharmacy Benefit Management (PBM), which manages approximately 15 million lives.
Key Financial Metrics
| Metric | Fiscal 2003 | Fiscal 2002 |
|---|---|---|
| Net Sales | $26,588.0 million | $24,181.5 million |
| Gross Margin | $6,863.0 million | $6,068.8 million |
| Operating Profit | $1,423.6 million | $1,206.2 million |
| Net Earnings | $847.3 million | $716.6 million |
| Diluted EPS | $2.06 | $1.75 |
| Total Assets | $10,543.1 million | $9,645.3 million |
| Long-term Debt | $753.1 million | $1,076.3 million |
| Shareholders' Equity | $6,021.8 million | $5,197.0 million |
Product Mix (2003): Prescription drugs accounted for 69% of net sales, followed by general merchandise (15%), over-the-counter/personal care (10%), and beauty/cosmetics (6%).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10% year-over-year, driven by pharmacy sales growth outpacing front store sales.
- Profitability: Operating profit rose 18% to $1.42 billion, and net earnings increased 18% to $847.3 million.
- Debt Reduction: Long-term debt decreased significantly by approximately $323 million (from $1.08 billion to $753 million), indicating improved leverage.
- Store Count: The total number of stores increased to 4,179, up from 4,087 in 2002. This included the opening of 150 new stores and the relocation of 125 stores in 2003.
- Market Expansion: The company entered new markets including Chicago, Las Vegas, Phoenix, and several in Florida and Texas.
Guidance, Outlook, and Risks
Outlook and Strategy:
- Store Development: CVS expects to open approximately 225-250 new or relocated stores in 2004, with about 100 in new markets.
- Technology: Continued investment in systems like EPIC (Excellence in Pharmacy Innovation and Care) and AIM (Assisted Inventory Management) to improve service and reduce costs.
- Loyalty: The ExtraCare program has 44 million members, serving as a key driver for front store sales and customer retention.
Risks and Contingencies:
- Legal Proceedings: The company is defending against a consolidated securities fraud class action lawsuit filed in 2001 regarding stock purchases between February and October 2001. The motion to dismiss was denied in December 2002, and discovery is ongoing.
- Government Investigation: CVS is cooperating with an investigation by the Rhode Island State Police and Attorney General regarding business relationships between certain state officials and Rhode Island companies, including CVS.
- Competition: The retail drugstore industry is highly competitive, with competition based on location, service, product selection, and price from various chains, supermarkets, and internet pharmacies.
Investor Verification Checklist
- Legal Exposure: Monitor the status of the consolidated securities litigation and the Rhode Island state investigation for potential financial impact.
- Debt Management: Verify the sustainability of the debt reduction trend and the company's reliance on commercial paper and sale-leaseback transactions for working capital.
- Store Economics: Assess the performance of the 150 new stores opened in 2003 and the projected 225-250 openings for 2004 to ensure they meet profitability targets.
- Pharmacy vs. Front Store Mix: Track the continued shift in revenue mix toward prescription drugs (69% of sales) and the impact of managed care pricing on margins.
- Dividend Consistency: Confirm the continuation of the quarterly cash dividend of $0.0575 per share, which has been paid consistently since the company went public.